title: Current and future vaccines and vaccination strategies against infectious laryngotracheitis (ILT) respiratory disease of poultry.
abstract: Infectious laryngotracheitis (ILT) is an economically important respiratory disease of poultry that affects the industry worldwide. Vaccination is the principal tool in the control of the disease. Two types of vaccines, live attenuated and recombinant viral vector, are commercially available. The first generation of GaHV-1 vaccines available since the early 1960's are live viruses, attenuated by continuous passages in cell culture or embryos. These vaccines significantly reduce mortalities and, in particular, the chicken embryo origin (CEO) vaccines have shown to limit outbreaks of the disease. However, the CEO vaccines can regain virulence and become the source of outbreaks. Recombinant viral vector vaccines, the second generation of GaHV-1 vaccines, were first introduced in the early 2000's. These are Fowl Pox virus (FPV) and Herpes virus of turkeys (HVT) vectors expressing one or multiple GaHV-1 immunogenic proteins. Recombinant viral vector vaccines are considered a much safer alternative because they do not regain virulence. In the face of challenge, they improve bird performance and ameliorate clinical signs of the disease but fail to reduce shedding of the challenge virus increasing the likelihood of outbreaks. At the moment, several new strategies are being evaluated to improve both live attenuated and viral vector vaccines. Potential new live vaccines attenuated by deletion of genes associated with virulence or by selection of CEO viral subpopulations that do not exhibit increased virulence upon passages in birds are being evaluated. Also new vector alternatives to express GaHV-1 glycoproteins in Newcastle diseases virus (NDV) or in modified very virulent (vv) serotype I Marek's disease virus (MDV) were developed and evaluated.
authors.affiliation: Poultry Diagnostic and Research Center, Department of Population Health, College of Veterinary Medicine, University of Georgia, 953 College Station Rd., Athens, GA, 30602, USA.. Electronic address: mcgarcia@uga.edu.
authors.forename: Maricarmen
authors.initials: M
authors.lastname: García
mesh_terms: D000818:Animals; D002645:Chickens / Q000276:immunology*; D005586:Fowlpox / Q000517:prevention & control* / Q000821:virology; D005587:Fowlpox virus / Q000276:immunology; D006566:Herpesviridae Infections / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D001352:Herpesvirus 1, Gallid / Q000276:immunology*; D009521:Newcastle Disease / Q000517:prevention & control* / Q000821:virology; D009522:Newcastle disease virus / Q000276:immunology; D011200:Poultry; D011201:Poultry Diseases / Q000517:prevention & control* / Q000821:virology; D014421:Turkey / Q000453:epidemiology; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines / Q000008:administration & dosage
chemical_list: D014765:Viral Vaccines
keywords: Chicken embryo origin (CEO) vaccine; Fowl-pox virus (FPV); Gallid herpesvirus 1 (GaHV-1); Herpes virus of turkey (HVT); Infectious laryngotracheitis (ILT); Marek’s disease (MD); Newcastle disease virus (NDV); Tissue culture origin (TCO) vaccine